Načítá se...
Increased MALAT1 expression contributes to cisplatin resistance in non-small cell lung cancer
Cisplatin-based chemotherapy is commonly used for the clinical treatment of patients with non-small cell lung cancer (NSCLC). However, the anti-tumor efficacy of cisplatin is limited by poor clinical response and the development of chemoresistance. At present, the underlying mechanism for cisplatin...
Uloženo v:
| Vydáno v: | Oncol Lett |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
D.A. Spandidos
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144744/ https://ncbi.nlm.nih.gov/pubmed/30250547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2018.9293 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|